Skip to main content
. 2023 Aug 18;24(16):12930. doi: 10.3390/ijms241612930

Figure 2.

Figure 2

Alpha-mangostin (α-MG) inhibited the TRPV3 current more effectively than other TRP channels. (A) Representative I–V curves from whole-cell recordings illustrate the inhibitory effect of 0.3 µM alpha-mangostin on TRPV4 and TRPA1 channels (GSK101: GSK-1016790A, a TRPV4 agonist; RR: ruthenium red, a TRP inhibitor; AITC: allyl isothiocyanate, a TRPA1 agonist; A967: A-967079, a TRPA1 inhibitor). Currents were elicited with ramp pulses from −100 to +100 mV over 1 s, which were repetitively applied every 20 s; the holding potential was set at 0 mV. (B) Summary of the inhibition percentage after 0.3 µM alpha-mangostin treatment at −100 mV. (C) The dose–response curve of indicated channel currents by alpha-mangostin in comparison with TRPV3 from Figure 1A (IC50 = 0.077 ± 0.013 µM, IC50 = 8.470 ± 1.725 µM, and IC50 = 5.092 ± 2.213 µM for TRPV3, TRPV4, and TRPA1, respectively).